A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults

简要总结

主要结局

次要结局

• Proportion of participants who achieve complete response, partial response or stable disease (Disease Control Rate (DCR)).(Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression.)
• Incidence of treatment-emergent Adverse Events (TEAEs) including nonserious Adverse Events (AEs), and Serious Advers Events (SAEs).(Up to 42 months or disease progression)
• Change in pain(Change from baseline at each visit up to 42 months)
• Duration of response (DOR)(Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression)
• Time of response (TTR)(Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression)
• Pattern of use of nivolumab under real-world practice conditions.(Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression)
• Tumor median progression-free survival (PFS) time(Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression)
• Proportion of participants who achieve partial or complete response (Objective Response Rate (ORR))(Every month until month 4, and every 3 months after month 4 up to 42 month or disease progression)
• Pattern of use of cabozantinib under real-world practice conditions.(Every month until month 4, and every 3 months after month 4 up to 42 months or disease progression)
• Change in disease-related symptoms(Change from baseline at each visit up to 42 months)
• Percentage of participants receiving subsequent anticancer therapies following cabozantinib and nivolumab discontinuation(Up to 42 months.)